Drugs / CBG166
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06461624 | Jul 2024 → Jul 2027 expected | hepatocellular carcinoma | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBG166 | “All subjects were intravenous administrated with CBG166.” NCT06461624 ↗ |
| Route | Intravenous | “All subjects were intravenous administrated with CBG166.” NCT06461624 ↗ |